Member Info for Shukan

there is a program on BBC Player - Science/Nature called
War in the Blood -A cure for cancer?
Documentary on two patients who were trialed for CAR-T therapy- for those invested a must watch on the difficulties of human trials

Moving on -couldn’t be more transparent

Speaking to Peter Redmond in reference to the placing - it was deemed essential as the company needed to move on with its portfolio, shareholders will hear news of this within due course, he said he was very excited and that Vlad was working very hard, they realise the PR front is something to be addressed.

You hit the nail on the head

Ten Days to roll out - part 1
https://twitter.com/hemogenyx/status/1225227373949472770?s=21

You have not learned any lesson - you are not an investor
But play with pennies to make pennies - this stock is not for you

Indeed-

IPO 3.5p -

U ain’t seen anything yet - #jpmorgan2020

I spoke with Peter Redmond last night - the company is at a crossroads with lots of upside and news flow for 2020 since the announcement of CAR-T they have opened the door to Global Pharma indeed the company has been approached by interested parties this is separate to the existing collaboration on CDX-antibodies, they are also upping their game on the PR front .
Interesting times ahead for all

The antibody has been shown to be effective in vivo against AML-derived cells using the Company's proprietary humanised mice. These potential applications of the CDX product candidate could provide life-saving treatments against three forms of blood cancer which remain resistant to current modes of treatment.

Statement from one of the directors
“It means we are on the way to a direct cure for the most common and for the majority of sufferers deadly forms of leukaemia - which was not even on the agenda when the company came to market”

Not forgetting the NASDAQ Global Pharma partner development

I will ring Peter tomorrow-

I hope you saw today's announcement which is very significant progress. Vladik has been working on it for some time but we could not announce till the results of the lab tests were known and positive. It means we are on the way to a direct cure for the most common and for the majority of sufferers deadly forms of leukaemia - which was not even on the agenda when the company came to market. I hope people understand that this is important news. And there is more in pipeline. I am happy for you to pass this on and I am happy to talk to you if you wanted to call.

"I am getting ready for the #JPM2020 #JPMorgan conference in San Francisco in January. Some say it is a zoo and useless, for me this one promises a lot of already scheduled meetings with potential partners and investors. Suddenly, I am a hot commodity!" Dr Sandler

"HEMO-CAR was able to programme human T cells (converted them into HEMO-CAR-T) to identify and destroy human AML derived cells in vitro" spiked at 6p+ last time

no

undervalued

#JPM2020 # indeed a hot commodity apparently -with this RNS its a game changer again for the company also that global pharma partner in for the ride - interesting Year ahead